Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARTNER: Olaparib plus platinum-based neoadjuvant chemotherapy in triple-negative and/or gBRCA breast cancer
2015-002811-13Phase 2Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of olaparib in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoints: pathological complete response at surgery and safety and tolerability of olaparib plus platinum-based chemotherapy. Status: unknown.
02
Drugs
olaparib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2015-002811-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002811-13.